Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Medtronic
McKinsey
Mallinckrodt
Express Scripts

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Etravirine - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for etravirine and what is the scope of freedom to operate?

Etravirine is the generic ingredient in one branded drug marketed by Janssen R And D and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Etravirine has one hundred and forty-three patent family members in thirty-nine countries.

There are five drug master file entries for etravirine. One supplier is listed for this compound.

Summary for etravirine
Recent Clinical Trials for etravirine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Veloxis PharmaceuticalsPhase 4
Temple UniversityPhase 4
Fundacio Lluita Contra la SIDAPhase 1

See all etravirine clinical trials

Synonyms for etravirine
0C50HW4FO1
269055-15-4
394729-17-0
3m8p
4-((6-amino-5-bromo-2-((4-cyanophenyl) amino) pyrimidin-4-yl) oxy)-3, 5-dimethylbenzonitrile
4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile
4-((6-Amino-5-bromo-2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy)-3,5-dimethylbenzonitrile
4-({6-amino-5-bromo-2-[(4-
4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE
4-(6-Amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile
4-(6-amino-5-bromo-2-(4-cyanophenylamino)pyrimidin-4-ylamino)-3,5-dimethylbenzonitrile
4-(6-amino-5-bromo-2-(4-cyanophenylamino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile
4-[[4-amino 5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]-amino]benzonitrile
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]-benzonitrile
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]-benzonitrile;
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile
4-[[6-amino-5-bromo-2-(4-cyanoanilino)-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile
4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3, 5 Cdimethylbenzonitrile
4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl benzonitrile
4-[[6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]-4-PYRIMIDINYL]OXY]-3,5-DIMETHYLBENZONITRILE
4-[6-amino-5-bromo-2-(4-cyano-phenylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile
4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethyl-benzonitrile
4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile
4-[6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL]OXY-3,5-DIMETHYL-BENZONITRILE
4-[6-azanyl-5-bromanyl-2-[(4-cyanophenyl)amino]pyrimidin-4-yl]oxy-3,5-dimethyl-benzenecarbonitrile
4CA-0516
65B
A818671
AB0030712
AB01566873_01
ABP001081
AC-8503
AC1L4XC5
ACM1142096067
ACM1189671484
AKOS015896355
AM20080899
AN-6704
API0007220
B-1795
BC004800
BC228657
BCP03562
BCP0726000193
BCP9000006
BDBM50103642
Benzonitrile, 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-
Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-
Benzonitrile,4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-
C20H15BrN6O
cc-89
CHEBI:63589
CHEMBL308954
CM14420
CS-0435
CTK4I1392
cyanophenyl)amino]pyrimidin-4-yl}oxy)-3,5-
D04112
DAPY deriv
DB-067700
DB06414
Diaminopyrimidine deriv
DTXSID30181412
EBD13985
Etravine; Etravirine
Etravirine (JAN/USAN/INN)
Etravirine (TMC125)
Etravirine [USAN:INN:BAN:JAN]
Etravirine-d8
etravirine;
FT-0658058
HE-0088
HMS3651P20
HY-90005
I06-1887
Intelence
Intelence (TN)
Intelence(TM)
J-513179
KB-51834
MFCD09837879
MolPort-009-194-145
PB32778
PubChem22565
PYGWGZALEOIKDF-UHFFFAOYSA-N
R 165335
R-165335
R165335
R165335-TMC125
R165335;
R165355;
RP17742
RTX-010809
s3080
SC-44935
SCHEMBL52691
SR-01000944895
SR-01000944895-1
ST1251359
SW219570-1
TMC 125
TMC 125;
TMC-125
TMC-125;
TMC-125/R-165335
TMC125
UNII-0C50HW4FO1
X2931
ZINC602632

US Patents and Regulatory Information for etravirine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-002 Dec 22, 2010 RX Yes Yes   Start Trial   Start Trial   Start Trial
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-003 Mar 26, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-001 Jan 18, 2008 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for etravirine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-002 Dec 22, 2010   Start Trial   Start Trial
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-003 Mar 26, 2012   Start Trial   Start Trial
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-001 Jan 18, 2008   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for etravirine

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1002795 300373 Netherlands   Start Trial 300373, 20191101, EXPIRES: 20230827
1002795 C01002795/01 Switzerland   Start Trial PRODUCT NAME: ETRAVIRIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58483 13.05.2008
1002795 PA2008016,C1002795 Lithuania   Start Trial PRODUCT NAME: ETRAVIRINUM; REGISTRATION NO/DATE: EU/1/08/468/001 20080828
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Express Scripts
Dow
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.